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1758Objective: To compare the 1-year results after aortic valve-sparing (AVS) or valve-replacing (AVR) aortic root
replacement from a prospective, international registry of 316 patients with Marfan syndrome (MFS).
Methods: Patients underwent AVS (n ¼ 239, 76%) or AVR (n ¼ 77, 24%) aortic root replacement at
19 participating centers from 2005 to 2010. One-year follow-up data were complete for 312 patients (99%),
with imaging findings available for 293 (94%). The time-to-events were compared between groups using
Kaplan-Meier curves and Cox proportional hazards models.
Results: Two patients (0.6%)—1 in each group—died within 30 days. No significant differences were found in
early major adverse valve-related events (MAVRE; P ¼ .6). Two AVS patients required early reoperation for
coronary artery complications. The 1-year survival rates were similar in the AVR (97%) and AVS (98%) groups;
the procedure type was not significantly associated with any valve-related events. At 1 year and beyond, aortic
regurgitation of at least moderate severity (2þ) was present in 16 patients in the AVS group (7%) but in no
patients in the AVR group (P ¼ .02). One AVS patient required late AVR.
Conclusions: AVS aortic root replacement was not associated with greater 30-day mortality or morbidity rates
than AVR root replacement. At 1 year, no differences were found in survival, valve-related morbidity, or
MAVRE between the AVS and AVR groups. Of concern, 7% of AVS patients developed grade 2þ aortic
regurgitation, emphasizing the importance of 5 to 10 years of follow-up to learn the long-term durability of
AVS versus AVR root replacement in patients with MFS. (J Thorac Cardiovasc Surg 2014;147:1758-67)Supplemental material is available online.
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Abbreviations and Acronyms
AR ¼ aortic regurgitation
AVR ¼ aortic valve-replacing
AVS ¼ aortic valve-sparing
MAVRE ¼ major adverse valve-related event
MFS ¼ Marfan syndrome
NSVD ¼ nonstructural valve dysfunction
NYHA ¼ New York Heart Association
SVD ¼ structural valve deterioration
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Dthe fibrillin-1 protein, resulting from variousFBN1 genemu-
tations. The aortic root is especially prone to dilatation and
dissection.2 By some estimates, about 80% of adult patients
with MFS will have dilated aortic roots.3
Before the introduction of aortic valve and ascending aorta
replacement by Bentall and DeBono4 in 1968, followed by
the advent of aortic valve-sparing (AVS) aortic root replace-
ment (remodeling technique of Yacoub and colleagues5 in
1979 and the reimplantation procedure of David and Fein-
del6 in 1988), the life expectancy of most patients with
MFS did not exceed 40 years.7 Numerous modifications
were subsequently introduced, including a recently devel-
oped computer-modeled custom external aortic root support
device.8 The hope was that lifelong anticoagulation (manda-
tory after an aortic valve-replacing [AVR] procedure using a
mechanical valve) could be avoided if the valve were pre-
served6,9; however, the potential for valve deterioration and
the need for reoperation was unknown. Although many
single-center analyses have reported mid-term success after
AVS root replacement using theDavid andFeindel reimplan-
tation technique, the native valve durability remains unclear
because of limited follow-up durations, retrospective
designs, single-center reporting, and insufficient sample
sizes. A recent meta-analysis by Benedetto and colleagues10
provided more insight; however, the results were concerning
in that patients with MFS had a substantially greater risk of
reoperation after an AVS procedure than after an AVR
procedure.
This first prospective, multicenter, international registry
study—Aortic Valve Operative Outcomes in Marfan
Patients—was initiated to provide contemporary data
regarding the clinical outcomes of AVS versus AVR aortic
root replacement. We report the 1-year results for 316
patients with MFS who were enrolled in this registry.METHODS
Study Design and Patient Recruitment
Patient enrollment continued from March 2005 until November 2010,
when the enrollment target of 316 patients was reached. The Data
Coordinating Center with 4 Study Cores coordinated the efforts of the
19 participating study centers (see the ‘‘Acknowledgment’’ section). After
the preliminary analysis,11 the target sample sizewas increased from 250 toThe Journal of Thoracic and Car316 patients to allow detection of a 2.3-fold difference between the AVR
and AVS groups in the risk of valve-related complications.12
The enrolled patients had confirmed MFS, had undergone AVS or AVR
aortic root replacement, and were available for follow-up. No limitations
regarding age, gender, previous cardiovascular intervention, or surgery
acuity were included. The type of surgical repair was dependent on the
patient’s clinical situation and surgeon and patient preference. Using the
1996 Ghent nosology,13 the Marfan Diagnostic Core (Johns Hopkins)
confirmed the MFS diagnosis clinically for all patients.
Each participating institution’s institutional review board or ethics com-
mittee approved the study protocol. Each patient gave written informed
consent. The protected health informationwas coded. The funding agencies
outside of Baylor College of Medicine had no role in data interpretation.
Data Collection and Definitions
The data collection and definitions had been previously described in
detail.11 The clinical data were collected preoperatively, at discharge,
and 6, 12, 24, and 36 months postoperatively. Echocardiograms were
obtained at the same times if possible or whenever available otherwise
and were analyzed by the Imaging Core (Mayo Clinic). When digital
images were not available, the echocardiographic reports were substituted.
The 1-year follow-up period extended from 274 to 457 postoperative days
(12  3 months). The AVS and AVR groups were formed according to the
initial operation performed; the AVS procedures were classified according
to the definitions suggested by Miller.14
Valve-related morbidity and mortality were initially defined according
to the 1996 American Association for Thoracic Surgery and Society of
Thoracic Surgeons guidelines.15 Valve-related complications included
structural valvular deterioration (SVD), nonstructural valve dysfunction
(NSVD), valve thrombosis, embolism, and bleeding. The consequences
of morbid events were defined as reoperation on the aortic valve,
valve-related mortality, sudden unexplained death, cardiac death, death
from any cause, and permanent valve-related impairment. The 2008
revision of the American Association for Thoracic Surgery, Society of
Thoracic Surgeons, and European Association for Cardio-Thoracic
Surgery valve-reporting guidelines16 introduced an updated composite
indicator to capture all types of valve-related events—major adverse
valve-related events (MAVRE)—which we used as a primary endpoint.
The MAVRE variable was defined as all-inclusive valve-related morbidity
and mortality and the need for permanent pacemaker or defibrillator
implantation within 14 days of valve intervention.
The patients were categorized as having SVDorNSVD if they had echo-
cardiographic aortic regurgitation (AR) grade2þ or a decline by1 New
York Heart Association (NYHA) functional class caused by impairment of
the operated valve, pursuant to the 2008 guidelines.16 (This method of cate-
gorization violated the guidelines in that AR grade 1þ was not considered
NSVD; see the justification in the ‘‘Discussion’’ section). Conversion from
AVS to AVR surgery or from 1 type of AVR to another during the same
operation was considered to indicate NSVD. Bleeding was classified as a
valve-related event if it occurred after hospital discharge and caused death,
hospitalization, or permanent injury or necessitated transfusion, regardless
of whether the patient was taking anticoagulant or antiplatelet drugs. Early
postoperative bleeding events, such as mediastinal hemorrhage requiring
re-exploration, were recorded separately and were not categorized as
valve-related complications. The definitions of non–valve-related cardiac,
pulmonary, and renal complications have been described previously.11
Patients and Operations
Of the 375 consecutively screened patients who had a tentative MFS
diagnosis, needed aortic root replacement, and agreed to participate in
the present study, 316 (84%) met the inclusion criteria and were enrolled
at 19 participating centers (Table E1). The 59 excluded patients included
54 who did not meet the Ghent criteria and 5 who had undergone isolated
valve replacement instead of root replacement. The types of aortic rootdiovascular Surgery c Volume 147, Number 6 1759
TABLE 1. Operative details
Operative variable Total (n ¼ 316) AVR (n ¼ 77) AVS (n ¼ 239) P value
Urgency of surgery
Elective 288 (91) 59 (77) 229 (96) <.01
Urgent 12 (4) 7 (9) 5 (2)
Emergency 16 (5) 11 (14) 5 (2)
Perfusion technique
Cardiopulmonary bypass alone 246 (78) 55 (71) 191 (80) .1
Circulatory arrest 70 (22) 22 (29) 48 (20) .1
HCAwithout perfusion adjuncts 25 (36) 7 (32) 18 (38) 1.0
HCAwith ACP 19 (27) 6 (27) 13 (27)
HCAwith RCP 23 (33) 8 (36) 15 (31)
HCAwith ACP þ RCP 3 (4) 1 (5) 2 (4)
Cardiopulmonary bypass time (min) 179 (141-256) 152 (115-197) 194 (148-270) <.01*
Aortic crossclamp time (min) 145 (110-208) 115 (79-161) 156 (117-221) <.01*
Operative time (min) 340 (266-429) 340 (245-405) 340 (275-441) .1*
Concomitant procedures
Hemiarch 52 (17) 15 (20) 37 (16) .4
Full arch (without elephant trunk) 5 (2) 0 5 (2) .2
Elephant trunk and arch 9 (3) 5 (6) 4 (2) .03y
Mitral valve replacement 6 (2) 5 (6) 1 (0.4) <.01y
Mitral valve repair 35 (11) 10 (13) 25 (10) .5
Coronary artery bypass 13 (4) 4 (5) 9 (4) .5*
Data presented as n (%) or median (interquartile range). AVR, Aortic valve-replacing; AVS, aortic valve-sparing; HCA, hypothermic circulatory arrest; ACP, antegrade cerebral
perfusion; RCP, retrograde cerebral perfusion. *Independent samples Mann-Whitney U test. yFisher’s exact test.
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Dreplacement procedures and operative details are listed in Table E2 and
Table 1, respectively. No female patients were pregnant at surgery. Of
the 316 patients, 239 (76%) underwent an AVS procedure.
Follow-up Data
Complete 30-day and in-hospital outcome data were obtained for all
314 surviving patients. The Imaging Core had discharge echocardiographic
images available for 240 patients (76%) and echocardiographic reports
for 61 (19%), for a total of 301 (95%). Twenty-five (8%) of these patients
had been treated at study sites that only assessed postprocedural AR
echocardiographically during surgery and not at discharge; these patients’
intraoperative postprocedural echocardiogram or report was used instead.
At1 year, clinical follow-up data were available for 300 (97%) of the
310 surviving patients; 4 patients (1%) had been lost to follow-up, 4 (1%)
had only echocardiographic follow-up data available, and 2 (1%) had
follow-up data from a patient interview. The vital status for patients without
clinical follow-up or interview data available was cross-checked with the
Social Security Death Index. Clinical follow-up data within the 1-year
point was available for 208 patients (69%); the remaining 92 (31%) had
clinical follow-up data available for>1 year.
The results of the imaging studies obtained 1 year postoperatively
were available for 293 (95%) of 310 surviving patients (271 echocardio-
grams read by the Imaging Core, 20 echocardiogram reports, and 2
electrocardiogram-gated magnetic resonance images). In 5 of the 271
echocardiograms read by the Imaging Core, technical obstacles precluded
assessment of AR severity; therefore, local echocardiographic reports were
used. For 122 patients (39%), the first follow-up echocardiogram or report
was obtained beyond the 1-year follow-up window. For analysis purposes,
the duration of clinical and echocardiographic follow-up was truncated at
457 days, except for 8 patients with later echocardiograms that showed AR
grade2þ. In those 8 cases, the actual echocardiographic follow-up period
was used in the analyses. No echocardiographic follow-up was
available for 17 patients (5%; 4 patients were lost to follow-up, 10 had
no follow-up echocardiograms, and 3 had echocardiograms or reports
that could not be retrieved from an outside medical institution).1760 The Journal of Thoracic and Cardiovascular SurStatistical Analysis
Normally distributed continuous data are summarized as the
mean standard deviation and compared between groups by using Student
t tests. Non-normally distributed continuous data are summarized as the
median and interquartile intervals, and the Mann-Whitney U test was
used for between-group comparisons. Nominal data are presented as
frequencies and percentages, and the chi-square or Fisher exact test was
used for between-group comparisons, as appropriate. Differences
associated with the operation type were assessed using Kaplan-Meier
curves, and log-rank tests were used to analyze the time-to-event for
each outcome variable, with statistical significance assessed by the
log-rank statistic at the .05 level.
Cox proportional hazards models were used to compare the risks
associated with patient characteristics (including demographic, pre-
operative, and operative variables) for each outcome while adjusting for
procedure type. Each predictor variable (Appendix E1) was independently
evaluated; only the predictors significant at the .05 level were subsequently
entered in a multivariable model adjusting for type of operation.RESULTS
Overall Outcomes
Early 30-day outcomes. One AVS patient died 1 day
postoperatively because of bleeding, and 1 AVR patient
died 7 days postoperatively of multiple organ failure, for
an early overall mortality rate of 0.6%. The incidence of
valve-related complications and MAVRE was 5% and
7%, respectively (Table 2). Valve-related morbid events
included 8 cases of NSVD; 6 occurred intraoperatively
and resulted in conversion from initial valve-sparing
(n¼ 5) or homograft root replacement (n¼ 1) to placement
of a mechanical composite valve graft.17 One other patient
required immediate reoperation to correct coronary arterygery c June 2014
TABLE 2. Thirty-day outcomes after aortic root replacement
Adverse event Total (n ¼ 316) AVR (n ¼ 77) AVS (n ¼ 239) P value
Mortality 2 (0.6) 1 (1) 1 (0.4) .4*
Valve-related events
NSVD 8 (3) 1 (1) 7 (3) 1.0*
Embolism 4 (1) 1 (1) 3 (1) 1.0*
Bleeding 5 (2) 2 (3) 3 (1) .6*
Permanent pacemaker within 14 d 5 (2) 2 (3) 3 (1) .6*
Valve-related morbidity 16 (5) 4 (5) 12 (5) 1.0*
MAVRE 21 (7) 6 (8) 15 (7) .6*
Mediastinal re-exploration 19 (6) 7 (9) 12 (5) .3*
Cardiac complications 64 (20) 27 (35) 37 (15) <.01
Atrial or ventricular arrhythmia 44 (14) 15 (20) 29 (12) .1
Pericardial effusion requiring drainage 10 (3) 4 (5) 6 (3) .3*
Cardiac failure 8 (3) 4 (5) 4 (2) .1*
MAVRE and cardiac complications 74 (24) 27 (36) 47 (20) .1
Pulmonary complications 26 (8) 12 (16) 14 (6) .01
Acute renal dysfunction 2 (1) 2 (3) 0 .1*
Total postoperative ventilation support time (h) 9 (5-17) 12 (8-24) 8 (5-15) <.01y
Total ICU stay (h) 32 (22-53) 46 (24-72) 26 (22-49) .02y
Length of hospital stay (d) 7 (5-9) 7 (6-10) 6 (5-9) .01y
Data presented as n (%) or median (interquartile range). No 30-day cases of SVD, reintervention on the aortic valve, or operated valvular endocarditis occurred. AVR, Aortic
valve-replacing; AVS, aortic valve-sparing; NSVD, nonstructural dysfunction; MAVRE, major adverse valve-related event; ICU, intensive care unit. *Fisher’s exact test.
yIndependent samples Mann-Whitney U test.
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Dkinking after an AVS operation (Florida sleeve procedure).
Another patient required repair of a coronary artery
pseudoaneurysm 6 days after an AVS procedure. The 4
cases of systemic embolism resulted in 2 reversible
ischemic neurologic deficits, 1 transient ischemic attack,
and 1 stroke. After discharge, 5 patients sustained valve-
related bleeding complications, including 3 cases of cardiac
tamponade requiring pericardial drainage, 1 of mediastinal
bleeding requiring re-exploration, and 1 of gastrointestinal
bleeding from an ulcer. Within 14 days postoperatively, 5
patients required a permanent pacemaker because of heart
block. No early cases of SVD, valve thrombosis, or
endocarditis occurred.
Twenty-seven bleeding events occurred before discharge
and were not classified as valve-related complications.
Eighteen necessitated mediastinal re-exploration, including
3 at the aortic root site (annular suture line or coronary
anastomoses) and 3 at a left atriotomy site or distal
aortic anastomosis. Of the 9 patients not requiring
re-exploration, 4 had cardiac tamponade (drained in 3,
treated conservatively in 1). Other bleeding sites included
the left groin, sternum, chest tube tract, lower extremity,
and an unidentifiable site.
Pericardial effusion requiring drainage occurred in
10 patients (bloody effusion in 8). One AVR patient
experienced a myocardial infarction. Overall, both cardiac
(P< .01) and pulmonary (P ¼ .01) complications were
more common in the AVR group (Table 2).
One-year outcomes. Six deaths occurred during the first
year. The causes of death after 30 days included 1 drowning
in the AVS group and 1 case of sepsis complicated byThe Journal of Thoracic and Carintracranial hemorrhage in the AVR group. In 2 AVS
patients, the exact cause of death was unknown but was
considered valve-related in accordance with the 2008
guidelines.16 At 1 year, the overall survival and freedom
from MAVRE was 98% and 86%, respectively (Table 3).
Eight patients (3%) were in NYHA class III-IV, and 16
(6%) had AR grade 2þ (Table E3).
The complications after 30 days included NSVD or
SVD (AR 2þ) detected echocardiographically in 16
patients. Echocardiography could not easily distinguish
between these modes of valve failure; thus, they were
combined into a single NSVD/SVD outcome. The first
echocardiographic examination available for 8 of these
patients was performed beyond the 1-year threshold.
The preoperative aortic valve morphology had been
normal in all 16 patients. These patients were more likely
than the other AVS patients to have had preoperative
AR 2þ (P ¼ .03), undergone AVS with the David I
technique (P ¼ .054), and had intraoperative, post-
procedural, mild AR (P<.01). Bleeding events occurred
in 3 patients, including bloody pleural effusion requiring
thoracentesis (day 33), gastrointestinal bleeding requiring
surgical intervention (day 199), and bloody pericardial
effusion (day 128) treated with transfusion and a change
in the anticoagulant regimen. Two patients experienced
embolic events: 1 transient ischemic attack (day 41) and
1 stroke (day 248). One patient developed endocarditis
(day 248). One AVS patient required surgical reinterven-
tion on the aortic valve and root for graft infection
(day 219). No patient developed valve thrombosis beyond
30 days.diovascular Surgery c Volume 147, Number 6 1761
TABLE 3. One-year operative outcomes after aortic root replacement
Adverse event Total (n ¼ 316) AVR (n ¼ 77) AVS (n ¼ 239) P value
Survival and freedom from valve-related events
Overall survival 98 (96-99), 6/316 97 (91-100), 2/77 98 (96-100), 4/239 .6
Freedom from valve-related events
Valve-related death 99 (97-100), 3/316 99 (93-100), 1/77 99 (97-100), 2/239 .7
NSVD/SVD 92 (89-95), 24/290 99 (92-100), 1/71 90 (85-93), 23/219 .04
Embolism 98 (96-99), 6/312 97 (91-100), 2/75 98 (96-100), 4/237 .6
Bleeding 97 (95-99), 8/312 93 (85-98), 5/75 98 (96-100), 3/237 .01
Endocarditis 100 (98-100), 1/316 99 (93-100), 1/75 100 (98-100), 0/237 .07
Reintervention 99 (98-100), 1/316 100 (95-100), 0/75 100 (98-100), 1/237 .6
Valve-related morbidity 89 (85-92), 35/312 91 (82-96), 7/77 88 (83-92), 28/235 .6
MAVRE 86 (81-90), 43/295 89 (80-95), 8/73 85 (79-89), 35/222 .5
MAVRE and cardiac complications 68 (63-74), 95/300 60 (48-71), 30/75 71 (65-77), 65/225 .04
Other complications
Cardiac complications 72 (23) 29 (37) 43 (18) <.01
Atrial or ventricular arrhythmia requiring treatment 51 (16) 17 (22) 34 (14) .1
Pericardial effusion requiring drainage 10 (3) 4 (5) 6 (3) .3
Cardiac failure 10 (3) 5 (6) 5 (2) .07
Pulmonary complications 30 (9) 13 (17) 17 (7) .01
Acute renal dysfunction 2 (1) 2 (3) 0 .1
Time-to-event estimates for survival and freedom from valve-related events were obtained using Kaplan-Mayer analysis and are presented as percentages (95% confidence
intervals), and number of events/number of observations at the beginning of the interval; ‘‘other complications’’ are reported as n (%). In 8 of 24 patients, NSVD/SVD due
to AR2þ was detected by echocardiography beyond the 1-year threshold because earlier echocardiograms for these patients were not available. These time-to-event outcomes
were compared using the log-rank statistic. No cases of valve thrombosis had developed by 1 year of follow-up. AVR, Aortic valve-replacing; AVS, aortic valve-sparing;
NSVD, nonstructural dysfunction; SVD, structural valve deterioration; MAVRE, major adverse valve-related events.
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DCardiac and pulmonary complications were both less com-
monafter the initial 30 days (Table 3). Tenpatients had cardiac
complications (days 32 to 419): 5 had atrial or ventricular ar-
rhythmias, 2 had heart block, 2 had congestive heart failure,
and 1 had myocarditis. Five pulmonary complications (which
developed from days 33 to 189) included 3 pleural effusions
requiring drainage and 2 cases of pneumonia.
Comparison of AVR and AVS Groups
The AVR patients were generally older and sicker than
the AVS patients. The AVR group had more patients in
NYHA class III-IV and with more severe AR, larger aortic
sizes, and a greater prevalence of ascending aortic
dissection, cardiomyopathy, and renal failure. Previous
cardiovascular operations (Table E1) and urgent or
emergency operations (Table 1) were more frequent in the
AVR group. The AVR group needed more concomitant
elephant trunk arch grafting or mitral valve replacement
than the AVS group (Table 1). In contrast, as expected,
the aortic crossclamp, cardiopulmonary bypass, and total
operative times were longer in the AVS group.
Early mortality did not significantly differ between the 2
groups (P¼ .4). The rates of early valve-related and cardiac
complications, MAVRE, and combined MAVRE and
cardiac complications were similar; however, pulmonary
problems were more prevalent in the AVR group, which
also had a longer mean ventilator support time. The
intensive care unit stay and overall hospital stay were
both longer for the AVR patients (Table 2).1762 The Journal of Thoracic and Cardiovascular SurThe Kaplan-Meier analysis of the 1-year outcomes re-
flected the between-group differences (Table 3, Figures 1
and 2). Although the major endpoints—including overall
survival (P ¼ .6), freedom from MAVRE (P ¼ .6), and
valve-related morbidity (P ¼ .7)—were similar between
the groups, freedom from combined NSVD/SVD was
greater in the AVR group (99%) than in the AVS group
(90%; P ¼ .04). AR of at least moderate severity (2þ)
was present in all 16 cases of combined NSVD/SVD that
developed after 30 days in the AVS group. In contrast,
only 1 patient had AR2þ in the AVR group. The freedom
from bleeding rate was 93% in the AVR group versus 99%
in the AVS group (P ¼ .01). The AVR patients had more
combined MAVRE and cardiac complications (57% vs
70%, P ¼ .006) than the AVS patients. The AVR group
also had more cardiac and pulmonary complications.
Overall, 7 patients were in NYHA class III and 1 was in
class IV. No significant difference was present between
the 2 groups (P ¼ .5; Table E3).
Cox regression analysis did not identify procedure type
as a risk factor for any of the 1-year adverse endpoints.
Of the covariates tested for inclusion in the Cox regression
model (Appendices E1 and E2), preoperative AR 2þ was
significantly associated with valve-related complications
(P ¼ .04), and intraoperative postprocedural AR was
significantly associated with MAVRE (P ¼ .03),
valve-related complications (P ¼ .02), and combined
NSVD/SVD (P< .01). Preoperative mitral regurgitation
2þ was significantly associated with combined MAVREgery c June 2014
FIGURE 1. Kaplan-Meier analysis of 1-year valve-related events comparing patients who underwent aortic valve-sparing (AVS) and aortic valve-replacing
(AVR) root replacement. The P value was obtained by computing the log-rank statistic. A, Freedom from major adverse valve-related events (MAVRE).
B, Freedom from nonstructural valve dysfunction/structural valve deterioration (NSVD/SVD).
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regurgitation2þwas also associated with a greater risk of
MAVRE (P ¼ .01), and preoperative tricuspid valve
regurgitation 2þ was associated with a greater risk of
bleeding (P¼ .04). However, the 95% confidence intervals
for the last 2 associations were wide because of the low
number of events during the first postoperative year.
DISCUSSION
The present study is the first prospective investigation to
compare the outcomes in patients with MFS concurrently
undergoing aortic root replacement using either the AVR
or AVS technique. The multicenter design enabled us to
determine whether the results would be ‘‘generalizable’’
around the world; it also allowed enough patients to be
enrolled within 5 years to potentially avoid the confound-
ing effects of changes in surgical technique. Although the
idea was appealing, it would have been unrealistic to
attempt to conduct this trial in a randomized fashion; we
decided it was in the patients’ interest to allow the
surgeons to perform whichever procedure they believed
was best for each patient in light of that patient’s particular
clinical circumstances.
Since this study began in 2005, newer techniques
for preserving the aortic valve have been developed.
Transcatheter aortic valve replacement has been gaining
popularity for elderly, very sick patients with aortic
stenosis18 and has been proposed as a potential ‘‘salvage’’
procedure if the preserved native aortic valve fails.
Treasure, Pepper, and Golesworthy and their colleagues
from London19 have developed a customized, computer-
designed external support mesh prosthesis that can beThe Journal of Thoracic and Carimplanted without cardiopulmonary bypass; they have
argued that this device can be used to prevent future aortic
root expansion when the patient has not yet reached the
conventional thresholds for surgical root replacement. It
cannot be used, however, if the patient has AR or if the
annulus is markedly dilated.
The present 1-year analysis has confirmed our previous
findings11 in a larger number of patients. The AVR group
was older, had more comorbidities, and more often required
emergency or urgent operations. The unadjusted log-rank
comparisons of valve-related complications showed a
greater prevalence of combined NSVD/SVD in the AVS
group. However, bleeding events, non–valve-related
cardiac adverse events, and pulmonary complications
were more common in the AVR group. The composite
MAVRE endpoint did not differ between the AVS and
AVR groups, apparently because the differences in
individual valve-related complications offset each other in
the composite MAVRE variable. Although the Cox
regression analysis showed that procedure type had no
important influence on any endpoint, the greater prevalence
of NSVD/SVD in the AVS group 1 year postoperatively
should serve as an alert—much longer follow-up is
necessary to reveal the true durability of the AVS approach
in patients with MFS. This observation reinforces the
conclusion of the recent meta-analysis by Benedetto and
colleagues,10 who examined 11 retrospective studies that
compared valve-related composite outcomes (ie, combined
reintervention, thromboembolic event, and endocarditis)
and individual complications after either AVS or AVR
root replacement in patients with MFS. They found no
difference in the composite outcome; however, the AVSdiovascular Surgery c Volume 147, Number 6 1763
FIGURE 2. Kaplan-Meier analysis of 1-year overall survival and freedom from valve-related events comparing patients who underwent aortic
valve-sparing (AVS) and aortic valve-replacing (AVR) root replacement. The P value was obtained by computing the log-rank statistic. A, Overall survival.
B, Freedom from valve-related complications. C, Freedom from combined major adverse valve-related events (MAVRE) and cardiac complications.
D, Freedom from bleeding.
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and the AVR patients had a greater incidence of thrombo-
embolic complications (these 2 individual complications
cancelled each other’s effects when combined in the
composite outcome variable).10 The greater 1-year
prevalence of NSVD/SVD in our study and the greater
reintervention rate reported by Benedetto and colleagues10
question the durability of the preserved native aortic valve
in patients with MFS. Future investigations that include
more patients followed up for long periods are clearly
necessary; such studies will also determine the mortality1764 The Journal of Thoracic and Cardiovascular Surrisk associated with reoperation after AVS procedures if
the valve fails.
Finally, the 2008 American Association for Thoracic
Surgery, Society of Thoracic Surgeons, and European
Association for Cardio-Thoracic Surgery valve-reporting
guidelines16 have stipulated that residual or recurrent mitral
or tricuspid regurgitation must be more than mild to qualify
as NSVD; however, no similar 2þ threshold has been
stated for AR after aortic valve repair or AVS aortic root
replacement. Because mild (1þ) AR is common after
AVS (occurring in 25% of AVS patients in the presentgery c June 2014
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overestimate the incidence of NSVD, and it would not
represent a clinically important complication. We suggest
that the next iteration of the valve-reporting guidelines be
modified according to these findings. The Stanford group
recently reported that mild (1þ) residual AR was
present in fully 43% of their patients 1 year after David
reimplantation AVS. However, it remained stable in 85%
to a median of 57 months, had progressed to 2þ in only
12% at a median of 28 months and remained stable
thereafter, and had degenerated to 4þ in only 1 patient.20
Hence, our present finding of a greater incidence of
NSVD/SVD in the AVS group probably did not portend
premature valve failure or the need for reoperation in the
medium term, and it certainly did not represent failure of
the fundamental valve-sparing concept in patients with
MFS.
Study Limitations
The limitations inherent in the present prospective
registry design included the impossibility of standardizing
surgical techniques and the possibility of important baseline
differences between patient groups. Additional limitations
of the study included its nonrandomized design, short
follow-up period (1 year), and the lack of imaging
information for 7% of the patients at 1 year. Another
challenge was accurately interpreting the echocardiograms:
various echocardiographic techniques were used, and the
quality of the images varied. Also, it was impossible to
discern in the AVS group whether the AR should represent
SVD or NSVD; thus, they were grouped together. Finally,
we had to rely on a 1-year echocardiographic report for
20 patients whose digital images were not obtainable or
interpretable. The original study was powered to detect a
2.3-fold increased risk of valve-related complications,
assuming 3 years of follow-up. Therefore, the 1-year
data analysis provided less power to detect significant
differences than the upcoming 3-year analysis because
fewer events had occurred at 1 year. Because of the
insufficient power and multiple hypothesis testing, the
1-year findings should be interpreted with caution.
Nonetheless, the data we have presented provide the best
comparison to date of the AVS and AVR approaches for
aortic root repair.
CONCLUSIONS
Despite the added complexity of AVS root replacement,
this approach was not associated with greater 30-day
mortality or a greater MAVRE rate than AVR root
replacement. At 1 year, no differences were found in
survival, valve-related morbidity, or MAVRE; however,
more bleeding events occurred after AVR and more valve
dysfunction (NSVD/SVD) after AVS. Of concern, 7% of
AVS patients developed 2þ AR during the follow-upThe Journal of Thoracic and Carperiod. This finding, combined with the increasing
popularity of AVS root replacement, mandates continued
follow-up of this well-defined cohort for 5 to 10 years to
evaluate the mid- and long-term durability of AVS versus
AVR root replacement in patients with MFS.The Marfan Foundation and the Data Coordinating Center at
Baylor College of Medicine express their gratitude to the domestic
and international study institutions whose contributions are
described below. The study could not have been conducted without
their tireless efforts in patient enrollment and data collection.
Stephen N. Palmer, PhD, ELS, contributed to the editing of the
manuscript. Scott A. Weldon, MA, CMI, contributed to figure
preparation.
Study institutions
Study Cores: Institution (Core Director)
Data Coordination Center and Surgical Core: Baylor College of
Medicine (J. S. Coselli, Study Principal Investigator)
Marfan Diagnostic Core: Johns Hopkins Hospital (H. C. Dietz)
Imaging Core: Mayo Clinic, Rochester (H. M. Connolly)
Genetic Repository: University of Texas Medical School at
Houston (D. M. Milewicz)
Participating Study Sites: Institution (Site Principal Investi-
gator, Number of Patients Enrolled)
Argentina: Institute of Cardiology and Cardiovascular
Surgery—Favaloro Foundation (R. R. Favaloro, 19 patients)
Canada: University of Ottawa Heart Institute (K-L. Chan, 3
patients)
Germany: HannoverMedical School (A. Haverich, 11 patients);
Medical University of Luebeck (H. H. Sievers, 13 patients);
University of Leipzig (F. W. Mohr, 21 patients)
The Netherlands: Leiden University Medical Center (M. I. M.
Versteegh, 3 patients)
United States: Baylor College of Medicine (J. S. Coselli, 15 pa-
tients); Central Maine Heart and Vascular Institute (R. P. Cochran,
C. Frumiento, 1 patient); Johns Hopkins Hospital (V. L. Gott, L. A.
Vricella, 32 patients); Loyola University Medical Center (J. P.
Schwartz, 3 patients); Mayo Clinic, Rochester (T. M. Sundt III,
H. V. Schaff, 55 patients); Missouri Baptist Medical Center
(N. T. Kouchoukos, 8 patients); Montefiore Medical Center
(A. DeAnda, 2 patients); New York Presbyterian–Cornell Hospital
(L. N. Girardi, 29 patients); Northwestern University Feinberg
School of Medicine (T. G. Gleason, C. Malaisrie, 8 patients);
Stanford University (D. C. Miller, 49 patients); University of
Pennsylvania (J. E. Bavaria, 28 patients); University of
Pittsburgh (T. G. Gleason, 2 patients); Washington University
(M. R. Moon, 14 patients).
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Dr Gosta Pettersson (Cleveland, Ohio). I represent myself and
Dr Stewart, who was the original discussant on this report.
I congratulate you for a nice presentation. I congratulate the group
for having put together this registry.
The inclusiveness is really the strength of the study, it represents
a real world experience. I am, however, in doubt about the ability
of this study to distinguish between the AVR and AVS procedures.
Nevertheless, this is a remarkable effort to provide better data on
how we should treat these patients, because there are still many
open questions.
There are 19 centers involved in this registry, but a few centers
have provided a larger number of patients. Is there anything to
learn about the learning curve of the AVS procedure from this?
Dr Coselli. Yes, 2 things. One, if you consider the 30-day data,
there were basically no deaths, no strokes, et cetera. The data from1766 The Journal of Thoracic and Cardiovascular Sur30 days were excellent for the groups from this collection of
institutions. So, consequently, there really was not much in the
way of an impact from a learning curve.
When we considered mortality and valve-related events and
the influence of the institution, we did not find that it was
statistically significant. However, the problem is that with 19
institutions and so many events, it defies a legitimate statistical
evaluation.
Dr Pettersson. The age range was from 4 to 70 years, and most
recently, the percentage of valve-sparing operations approached
100%. Have you identified any limitations, any contraindications
to valve-sparing? Also, what about age? The 4-year-old did not
make it, and you said it was nonvalve-related, but still that is an
interesting question.
Dr Coselli. I do not recall the exact numbers in the very low end
of the pediatric age group, but clearly the 4-year-old patient was a
bit of an outlier. However, when we considered age as a variable
for valve outcome and survival, it was not a statistically significant
factor.
Dr Pettersson.AVS was performed using a number of different
techniques. Did that have any effect on residual AR?
Dr Coselli. No, that did not arise. Again, it had to do with
the total number of events and the wide number of small
variations in technique. So, no, this particular evaluation could
not specifically answer that question.
Dr Pettersson. There were a larger number of bleeding events,
and you separated them into valve-related and nonvalve-related.
A valve-sparing procedure is a significantly longer operation
than just replacing the aortic valve—did that not affect bleeding?
Dr Coselli. That is very interesting. There was increased
complexity with AVS compared with a standard Bentall operation,
removing the patients who had undergone concomitant arch
operations, mitral valve repair, et cetera. Thus, although the
cardiopulmonary bypass times and crossclamp times were longer,
that did not influence the early results or, ultimately, the long-term
results.
Dr Pettersson. My final question relates to the conversions.
At which stage during the operation did the surgeons decide to
abandon trying to save the valve? Conversion after 2.5 hours of
crossclamp time is of great concern.
Dr Coselli. We described this group of 6 patients in our
2011 publication. Surgeons abandoned saving the valve if
post-procedural excessive aortic regurgitation could not be
corrected. While the crossclamp duration before conversion could
not be obtained, the total crossclamp time exceeded 3 hours
for 5 of the 6 patients. Except for one patient who developed
early cardiac tamponade and severe mitral valve regurgitation,
there were no short-term or follow-up complications in this
group.
Dr Pettersson. Thank you, and I also thank the Association for
the privilege to discuss this report.
Dr Marc R. Moon (St Louis, Mo). It is remarkable that
operative mortality only occurred in 2 patients with this very
complex procedure and complex disease. One of the problems
with developing a new innovative technique is that sometimes it
is not reproducible. However, Drs David and Yacoub hit the nail
on the head. They were able to develop an incredibly complex
procedure that is reproducible and safe.gery c June 2014
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Dr Hitoshi Ogino (Tokyo, Japan). Thank you very much for an
interesting study and presentation.
My questions are very simple. Unfortunately, some of the
patients developed a stroke during the operation or at the long-term
period. What was the cause of the embolism or stroke? What do
you think about that?
Dr Coselli. That I do not know in detail. There were 4 cases of
early and 2 cases of late embolism that will be described in the
upcoming publication.
Dr Ogino. Another question. Some patients developed AR at
the long-term period. What is the cause of the AR? Have you
analyzed it or did you study it?
Dr Coselli.We are still analyzing that. Again, the imaging core
is with Heidi Connolly at Mayo Clinic, and the numbers were still
small enough for analysis. However, it was basically leaflet
deterioration over time. We know that annular dilatation was not
an issue; thus, it was almost always leaflet deterioration.
But what we are going to have to eventually go back and study
and determine, and I think this is probably more the core of your
question, is whether any of those valve leaflets were prolapsing
below the annulus when the patient left the operating room. We
are still in the process of evaluating those sorts of factors, but do
not have the information for this particular presentation.
Dr Ogino. Thank you very much.The Journal of Thoracic and CarDr Marc R. Moon (St Louis, Mo). What is the planned
long-term follow-up for these patients, and is the study closed
now to accrual?
Dr Coselli. Yes. Accrual of the study has been completed. We
believe it is reasonably powered. It was initially set up as, in
effect, a short-term 3-year follow-up study.
If we can acquire the funding to continue to monitor these
patients and pull the data together at the core sites, we will try to
continue it for at least 10 years, although it would be ideal to
continue for even longer.
This was a unique group of patients because they were all fully
vetted for Marfan syndrome through a single, highly qualified
genetic program, and all the analysis of the imaging was
performed by a single renowned individual.
Thus, the follow-up has beenvery, very goodand the quality of the
data excellent. We will just have to see how this holds up over time.
Dr Leonard N. Girardi (New York, NY). You saw over time
that a move away from AVR occurred, and almost everybody
was undergoing AVS. Did you see a similar move away from
remodeling toward reimplantation?
Dr Coselli.Yes. Only 1 remodeling was performed in the whole
series, and this patient underwent intraoperative conversion.
Almost all these institutions had adopted the inclusion technique
and had moved away from the Yacoub technique very, very early
on, for all the reasons that we accept.diovascular Surgery c Volume 147, Number 6 1767
APPENDIX E1. VARIABLES TESTED FOR
INCLUSION IN REGRESSION MODEL
1. Type of surgery (AVR vs AVS)
2. Study site
3. Age at surgery
4. Gender
5. Race
6. Smoking status
7. Preoperative New York Heart Association class
8. Preoperative composite aortic regurgitation severity
9. Preoperative composite mitral regurgitation severity
10. Preoperative composite tricuspid regurgitation severity
11. Preoperative dissection
12. Preoperative dissection acuity
13. Preoperative aortic valve disease
14. History of mechanical composite valve graft surgery
15. History of aortic valve resuspension
16. History of homograft aortic root replacement
17. History of mitral valve replacement
18. History of mitral valve repair
19. Hypertension
20. Coronary artery disease
21. Heart failure
22. Cardiac arrest
23. Cardiac arrhythmia
24. Myocardial infarction
25. Endocarditis
26. Dialysis
27. Diabetes
28. Blood urea nitrogen/creatinine ratio
29. Operating surgeon
30. Crossclamp time
31. Cardiopulmonary bypass time
32. Concomitant surgical procedure
APPENDIX E2. KAPLAN-MEIER AND COX
REGRESSION ANALYSES
Kaplan-Meier Analysis
Kaplan-Meier curve analysis suggested that the AVR
patients were at greater risk of combined MAVRE and
cardiac complications (P ¼ .006) and bleeding (P ¼ .01)
than were the AVS patients. The AVS patients appeared to
have a greater risk of NSVD/SVD (P ¼ .04). The type of
surgery was not significantly associated with MAVRE
(P ¼ .6), overall mortality (P ¼ .6), valve-related mortality
(P ¼ .7), valve-related complications (P ¼ .7), embolism
(P ¼ .3), reintervention (P ¼ .6), or endocarditis (P ¼ .1).
Cox Regression Analysis
 MAVRE
The risk of MAVRE among patients with mitral
regurgitation (MR) grade 2þ was about 2.6 times
greater than among patients with none/trivial/grade
1þMR after adjustment for surgery type and postpro-
cedural intraoperative aortic regurgitation (AR;
P ¼ .01). The risk of MAVRE among patients with
postprocedural intraoperative AR grade 1þ was
2.2 times greater than among patients with no
postprocedural AR after adjustment for surgery type
and MR grade (P ¼ .03). The surgery type itself
was not significantly associated with MAVRE (hazard
ratio, 0.72; 95% confidence interval [CI], 0.3-1.8).
 Combined MAVRE and cardiac morbidity
After adjustment for composite MR severity
(P ¼ .005), the surgery type was no longer
significantly associated with combined MAVRE and
cardiac morbidity (P ¼ .75). The risk of experiencing
this combined event was about 2.2 times greater for
patients with MR grade 2þ than for patients with a
lower MR grade (none, trivial, or grade 1þ).
 Death from all causes
Patients with preoperative MR grade 2þ were more
likely to die of any cause than were those with a lower
MR grade (hazard ratio, 19.7; 95% CI, 1.6-247.9;
P ¼ .02) after adjustment for surgery type. We
considered this hazard ratio to be only an indication
of a possible relationship, not a reliable estimate,
because the 95% CI was extremely wide. The surgery
type was not associated with all-cause mortality
(P ¼ .52).
 Valve-related complications
The risk of valve-related complications among
patients with preoperative AR grade 2þ was 2.2
times (95% CI, 1.05-4.4; P ¼ .04) greater than it
was among patients with lower preoperative AR, after
adjustment for postprocedural intraoperative AR and
surgery type. Postprocedural intraoperative AR grade
1þ was associated with a 2.4-fold (95% CI,
1.2-4.8) increased risk of valve-related complications
after adjustment for surgery type and preoperative
AR. The surgery type was not a significant predictor
of valve-related complications after adjustment for
preoperative AR grade 2þ and postprocedural
intraoperative AR (P ¼ .57).
 Bleeding
The surgery type (P¼ .26) was no longer significantly
associated with bleeding after adjustment for tricuspid
regurgitation severity (P¼ .004). The risk of bleeding
among patients with tricuspid regurgitation severity
grades 2þ or 3þ was about 12.6 times (95% CI,
2.3-70.3) greater than that of patients with none,
trivial, or grade 1þ tricuspid regurgitation severity.
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We considered this hazard ratio to be only an
indication of a possible relationship, not a reliable
estimate, because the 95% CI was very wide.
 NSVD/SVD
Patients with postprocedural intraoperative AR were
4.0 times more likely (95% CI, 1.7-9.1) to have
NSVD/SVD than were patients who did not have
AR. The analysis was adjusted for surgery type, which
itself was not significantly associated with NSVD/
SVD (P ¼ .14).
 None of the predictor variables were significantly
associated with valve-related death, embolism, reinter-
vention, or endocarditis using Cox proportional hazards
modeling.
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TABLE E1. Patient characteristics
Variable Total (n ¼ 316) AVR (n ¼ 77) AVS (n ¼ 239) P value
Age (y) 35  13 (4-70) 39  14 (8-70) 33  13 (4-65) <.01
Male gender 203 (64) 55 (71) 148 (62) .1
Hypertension 68 (22) 21 (27) 47 (20) .2
Hypercholesterolemia 8 (3) 2 (3) 6 (3) 1.0*
Diabetes 2 (1) 0 2 (1) 1.0*
Smokingy (no. of observations) 315 77 238 .7
Current smoker 24 (8) 6 (8) 18 (8)
Former smoker 59 (19) 12 (16) 47 (20)
Recent cerebrovascular accident 0 0 0 NA
COPD 11 (4) 2 (3) 9 (4) 1.0*
Pneumonia .1
Current 1 (0.3) 1 (1) 0
Previous 12 (4) 5 (7) 7 (3)
Coronary artery disease 3 (1) 2 (3) 1 (0.4) .1*
MI within 24 h 1 (0.3) 0 1 (0.4) 1.0*
Cardiomyopathy .01
Current 7 (2) 5 (7) 2 (1)
Previous 3 (1) 1 (1) 2 (1)
MV disease .7
Current 192 (61) 50 (65) 142 (59)
MV prolapse 150 (47) 34 (44) 116 (49)
MV regurgitation 2þ 9 (3) 6 (8) 3 (1)
Combined 33 (10) 10 (13) 23 (10)
Previous 8 (3) 2 (3) 6 (3)
History of endocarditis 2 (1) 1 (1) 1 (0.4) .4*
Coagulopathy 6 (2) 3 (4) 3 (1) .2*
NYHA class .05
I 216 (68) 45 (58) 171 (72)
II 79 (25) 23 (30) 56 (23)
III 12 (4) 4 (5) 8 (3)
IV 9 (3) 5 (7) 4 (2)
NYHA class III-IV 21 (7) 9 (12) 12 (5) .06
Bicuspid aortic valve 8 (3) 3 (4) 5 (2) .4*
LVEF (%) 60 (55-65; 271) 60 (55-65; 66) 60 (55-65; 205) .2z
Sinus rhythm 309 (98) 75 (97) 234 (98) .7*
AR (no. of observations) 307 76 231 <.01
None/trivial (0) 123 (40) 17 (22) 106 (46)
Mild (1þ) 107 (35) 21 (28) 86 (37)
Moderate (2þ) 40 (13) 13 (17) 27 (12)
Moderate to severe (3þ) 14 (5) 10 (13) 4 (2)
Severe (4þ) 23 (8) 15 (20) 8 (4)
AR  2þ 77 (25) 38 (50) 39 (17) <.01
Aortic dimensions (mm)
Annulus 26 (23-28; 275) 26 (24-29; 67) 25 (23-27; 208) .01z
Sinuses of Valsalva 50 (47-53; 306) 53 (49-58; 74) 49 (46-52; 232) <.01z
Sinotubular junction 37 (33-43; 197) 39 (34-46; 50) 36 (32-41; 147) .05
Ascending aortic dissection 30 (10) 18 (23) 12 (5) <.01
Dissection type <.01
Acute 13 (4) 7 (9) 6 (3)
Chronic 17 (5) 11 (14) 6 (3)
Aortic rupture 1 (0.3) 0 1 (0.4) 1.0*
Previous CV surgery 29 (9) 17 (21) 12 (5) <.01
(Continued)
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TABLE E1. Continued
Variable Total (n ¼ 316) AVR (n ¼ 77) AVS (n ¼ 239) P value
Previous CVoperations (n) <.01
1 21 (7) 11 (14) 10 (4)
2 6 (2) 4 (5) 2 (1)
3 2 (1) 2 (3) 0
Previous CV surgery type
AV resuspension 1 (0.3) 1 (1) 0 .2*
AV replacement, CVG 2 (1) 2 (3) 0 .6*
Homograft root 1 (0.3) 1 (1) 0 .2*
MV repair/replacement 9 (3) 3 (4) 6 (3) .5*
Aortic aneurysm repair
Ascending aorta 4 (1) 3 (4) 1 (0.4) .05*
Descending thoracic aorta 5 (2) 3 (4) 2 (1) .1*
Abdominal aorta 4 (1) 2 (3) 2 (1) .3*
Aortic dissection repair
Stanford A 8 (3) 7 (9) 1 (0.4) <.01*
Stanford B 6 (2) 3 (4) 3 (1) .2*
Other 6 (2) 4 (5) 2 (1) .03*
Creatinine (mg/dL) 0.9 (0.7-1.0) 0.9 (0.8-1.1) 0.8 (0.7-1.0) <.01z
Renal failure <.01
Current 3 (1) 3 (4) 0
Previous 1 (0.3) 1 (1) 0
Data presented as mean  standard deviation (range), n (%), median (interquartile range), or median (interquartile range; number of observations). AVR, Aortic valve-replacing;
AVS, aortic valve-sparing;COPD, chronic obstructive pulmonary disease;MI, myocardial infarction;MV, mitral valve;NYHA, NewYorkHeart Association; LVEF, left ventricular
ejection fraction; AR, aortic regurgitation; CV, cardiovascular; AV, aortic valve; CVG, composite valve graft. *Fisher exact test. yPatients were considered nonsmokers if they had
stopped smoking 5 years before aortic root surgery. zIndependent samples Mann-Whitney U test.
TABLE E2. Types of aortic root replacement (n ¼ 316)
Root replacement type n (%)
Valve-replacing 77 (24)
Mechanical composite valve graft 63
Stented bioprosthetic composite valve graft 8
Stentless porcine root 4
Homograft root 2
Valve-sparing 239 (76)
Reimplantation 238
David V 144
Stanford modification 20
Other modifications 4
David I 79
David IV 14
Florida sleeve 1
Yacoub remodeling 1
TABLE E3. New York Heart Association class and aortic
regurgitation 1 year after aortic root replacement
Adverse event Total AVR AVS P value
NYHA class 294 71 223 .5
I 246 (78) 60 (78) 186 (78)
II 40 (13) 8 (10) 32 (13)
III 7 (2) 2 (3) 5 (2)
IV 1 (0.3) 1 (1) 0
Aortic regurgitation 288 71 217 .05
None/trivial (0) 206 (71) 60 (85) 146 (67)
Mild (1þ) 66 (23) 11 (15) 55 (25)
Moderate (2þ) 12 (4) 0 12 (6)
Moderate to severe (3þ) 3 (1) 0 3 (1)
Severe (4þ) 1 (0.3) 0 1 (0.5)
Aortic regurgitation 2 16 (6) 0 16 (7) .02
Data presented as n (%). AVR, Aortic valve-replacing; AVS, aortic valve-sparing;
NYHA, New York Heart Association.
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